ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 60.6 | 46.9 | 29.6 |
| Other income | 1.7 | 0.5 | 5.2 |
| Total income | 62.4 | 47.4 | 34.8 |
| Profit before exceptional items & tax | 5.1 | 2.1 | 2.5 |
| Profit before tax | 5.1 | 2.1 | 2.5 |
| Net profit | 4.4 | 1.6 | 1.9 |
| Operating margin | 8.2% | 4.4% | 7.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +131.60% |
|---|---|
| Net profit, quarter on quarter | +175.00% |
| Revenue, year on year | +104.70% |
BSE results filing, NSE: MEDICAMEQ. Figures extracted from the filing.
Medicamen Biotech Ltd: key numbers
- Share price
- ₹275.45
- Market cap
- ₹387.4 Cr
- Revenue (annual)
- ₹197.8 Cr
- Net profit (annual)
- ₹9.64 Cr
- P/E (TTM)
- 35.8×Sector 43.8×
- Promoter holding
- 42.57%+2.11% QoQ
- FII holding
- 4.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medicamen Biotech Ltd
All →Medicamen Biotech Board Meeting Date
Medicamen Biotech will meet on 13 Nov 2026 to consider half-yearly results for September 2026. Trading window stays closed from 01 Oct to 16 Nov 2026.
Medicamen Biotech Preferential Issue
Medicamen Biotech allotted 50 lakh equity shares at ₹530 per share under its preferential issue. The allotment raises ₹265 Crore in fresh equity capital.
- Value
- ₹265.0 Cr
Medicamen Biotech Preferential Issue
Medicamen Biotech allotted 5,00,000 equity shares at ₹530 each in a preferential issue to one investor. The allotment raised ₹26.5 Crore, taking paid-up capital to ₹14.06 Crore.
- Value
- ₹26.50 Cr
Medicamen Biotech Convertible Warrants
Medicamen Biotech allotted 5,00,000 equity shares to Shivalik Rasayan Ltd via warrant conversion at ₹530 each, raising ₹26.5 Crore. Paid-up capital rises to ₹14.06 Crore.
- Value
- ₹26.50 Cr
Medicamen Biotech Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended 30 September 2026.
Medicamen Biotech Other Announcement
Medicamen Biotech Limited's Director Sanjay Bansal sold 32,813 shares on the open market, as per a regulatory filing.
- Value
- ₹1.05 Cr